

Edgar Filing: BIOMET INC - Form 10-Q

BIOMET INC
Form 10-Q
April 10, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended February 28, 2006.

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____.

Commission file Number 0-12515.

BIOMET, INC.
(Exact name of registrant as specified in its charter)

Indiana
(State or other jurisdiction of
incorporation or organization)

35-1418342
(I.R.S. Employer
Identification No.)

56 East Bell Drive, Warsaw, Indiana 46582
(Address of principal executive offices)

(574) 267-6639
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is an accelerated filer (as
described in Rule 12b-2 of the Exchange Act). Yes No

Indicate by check mark whether the registrant is a shell company (as described
in Rule 12b-2 of the Exchange Act). Yes No

As of February 28, 2006, the registrant had 246,072,123 common shares
outstanding.

BIOMET, INC.

CONTENTS

Pages

Part I. Financial Information

Edgar Filing: BIOMET INC - Form 10-Q

Item 1.	Financial Statements:	
	Consolidated Balance Sheets	1-2
	Consolidated Statements of Income	3
	Consolidated Statements of Cash Flows	4
	Notes to Consolidated Financial Statements	5-7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	8-10
Item 3.	Quantitative and Qualitative Disclosure about Market Risks	11
Item 4.	Controls and Procedures	11
Part II.	Other Information	
	Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	12
	Item 5. Other Information	12
	Item 6. Exhibits	12
	Signatures	13
	Index to Exhibits	14

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BIOMET, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
at February 28, 2006 and May 31, 2005
(in thousands)

ASSETS

	February 28, 2006	May 31, 2005
	-----	-----
	(Unaudited)	
Current assets:		
Cash and cash equivalents	\$ 102,543	\$ 104,706
Investments	8,100	10,962
Accounts and notes receivable, net	498,761	479,745
Inventories	523,323	469,791
Deferred income taxes	76,087	72,732
Prepaid expenses and other	41,315	35,980
	-----	-----
Total current assets	1,250,129	1,173,916
	-----	-----
Property, plant and equipment, at cost	621,566	574,398
Less, Accumulated depreciation	280,694	251,511
	-----	-----
Property, plant and equipment, net	340,872	322,887
	-----	-----

Edgar Filing: BIOMET INC - Form 10-Q

Investments	59,193	61,406
Goodwill	432,966	435,621
Intangible assets, net	80,595	87,835
Other assets	14,212	14,912
	-----	-----
Total assets	\$2,177,967	\$2,096,577
	=====	=====

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
at February 28, 2006 and May 31, 2005
(in thousands)

LIABILITIES AND SHAREHOLDERS' EQUITY

	February 28, 2006	May 31, 2005
	-----	-----
	(Unaudited)	
Current liabilities:		
Short-term borrowings	\$ 273,723	\$ 282,193
Accounts payable	60,245	57,021
Accrued income taxes	9,764	9,725
Accrued wages and commissions	65,376	62,171
Other accrued expenses	97,094	90,281
	-----	-----
Total current liabilities	506,202	501,391
Long-term liabilities:		
Deferred income taxes	29,195	31,255
	-----	-----
Total liabilities	535,397	532,646
	-----	-----
Contingencies		
Shareholders' equity:		
Common shares	197,387	188,162
Additional paid-in capital	67,623	67,613
Retained earnings	1,375,532	1,284,905
Accumulated other comprehensive income	2,028	23,251
	-----	-----
Total shareholders' equity	1,642,570	1,563,931
	-----	-----
Total liabilities and shareholders' equity	\$2,177,967	\$2,096,577
	=====	=====

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME
for the nine and three month periods ended February 28, 2006 and 2005
(Unaudited, in thousands, except per share data)

Nine Months Ended		Three Months Ended	
	-----		-----
	2006	2005	2006
	-----	-----	-----

Edgar Filing: BIOMET INC - Form 10-Q

Net sales	\$1,485,847	\$1,376,857	\$ 506,254	\$ 482,023
Cost of sales	417,167	395,155	143,061	138,068
	-----	-----	-----	-----
Gross profit	1,068,680	981,702	363,193	343,955
Selling, general and administrative expenses	544,772	505,989	185,137	179,224
Research and development expense	63,182	58,543	21,063	20,461
In-process research and development	--	26,020	--	--
	-----	-----	-----	-----
Operating income	460,726	391,150	156,993	144,270
Other income, net	2,575	2,157	2,262	2,641
	-----	-----	-----	-----
Income before income taxes	463,301	393,307	159,255	146,911
Provision for income taxes	155,659	144,891	53,190	50,127
	-----	-----	-----	-----
Net income	\$ 307,642	\$ 248,416	\$ 106,065	\$ 96,784
	=====	=====	=====	=====
Earnings per share:				
Basic	\$1.24	\$.98	\$.43	\$.38
	=====	=====	=====	=====
Diluted	\$1.23	\$.97	\$.43	\$.38
	=====	=====	=====	=====
Shares used in the computation of earnings per share:				
Basic	248,270	253,000	246,859	252,182
	=====	=====	=====	=====
Diluted	249,202	255,029	247,772	253,994
	=====	=====	=====	=====
Cash dividends per common share	\$.25	\$.20	\$ --	\$ --
	=====	=====	=====	=====

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
for the nine months ended February 28, 2006 and 2005
(Unaudited, in thousands)

	2006	2005
	----	----
Cash flows from (used in) operating activities:		
Net income	\$307,642	\$248,416
Adjustments to reconcile net income to net cash from operating activities:		
Depreciation	51,062	45,001
Amortization	8,044	5,212
Write off of in-process research and development	--	26,020
Loss on sale of investments, net	1,166	103
Deferred income taxes	(5,368)	(3,159)
Changes in current assets and liabilities:		
Accounts and notes receivable, net	(29,654)	8,774
Inventories	(66,287)	(29,136)
Accounts payable	4,430	(1,519)
Accrued income taxes	(1,685)	(6,318)
Other	8,588	(8,678)
	-----	-----

Edgar Filing: BIOMET INC - Form 10-Q

Net cash from operating activities	277,938	284,716
	-----	-----
Cash flows from (used in) investing activities:		
Proceeds from sales and maturities of investments	48,209	41,630
Purchases of investments	(41,679)	(36,607)
Capital expenditures	(75,259)	(73,396)
Acquisitions, net of cash acquired	--	(266,229)
Other	305	(3,070)
	-----	-----
Net cash used in investing activities	(68,424)	(337,672)
	-----	-----
Cash flows from (used in) financing activities:		
Increase (decrease) in short-term borrowings, net	(4,680)	183,733
Issuance of common shares	12,598	19,466
Cash dividends	(62,473)	(50,872)
Purchase of common shares	(159,122)	(155,405)
	-----	-----
Net cash used in financing activities	(213,677)	(3,078)
	-----	-----
Effect of exchange rate changes on cash	2,000	(3,342)
	-----	-----
Decrease in cash and cash equivalents	(2,163)	(59,376)
Cash and cash equivalents, beginning of year	104,706	159,243
	-----	-----
Cash and cash equivalents, end of period	\$102,543	\$ 99,867
	=====	=====

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1: BASIS OF PRESENTATION.

The accompanying consolidated financial statements include the accounts of Biomet, Inc. and its subsidiaries (individually and collectively referred to as the "Company"). The unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine-month period ended February 28, 2006 are not necessarily indicative of the results that may be expected for the fiscal year ending May 31, 2006. For further information, refer to the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended May 31, 2005.

The accompanying consolidated balance sheet at May 31, 2005, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by accounting principles generally accepted in the United States.

The Company operates in one business segment, musculoskeletal products, which includes the designing, manufacturing and marketing of reconstructive products, fixation devices, spinal products and other products. Other products consist primarily of softgoods and bracing products, arthroscopy products, general instruments and operating room supplies. The Company manages its business segment primarily on a geographic basis. These geographic markets are

Edgar Filing: BIOMET INC - Form 10-Q

comprised of the United States, Europe and the Rest of World. Major markets included in the Rest of World geographic market are Canada, South America, Mexico, Japan and the Pacific Rim.

Net sales of musculoskeletal products by product category are as follows for the nine and three month periods ended February 28, 2006 and 2005:

	Nine Months Ended		Three Months Ended	
	2006	2005	2006	2005
	----	----	----	----
	(in thousands)			
Reconstructive Products	\$1,006,764	\$ 910,087	\$346,610	\$326,220
Fixation Devices	187,192	185,131	62,338	62,090
Spinal Products	164,267	158,756	53,914	52,615
Other Products	127,624	122,883	43,392	41,098
	-----	-----	-----	-----
Total	\$1,485,847	\$1,376,857	\$506,254	\$482,023
	=====	=====	=====	=====

As permitted by SFAS No. 123, the Company accounts for its employee stock options using the intrinsic value method. Accordingly, no compensation expense is recognized for the employee stock-based compensation plans. If compensation expense for the Company's employee stock options had been determined based on the fair value method of accounting, pro forma net income and diluted earnings per share for the nine and three month periods ended February 28, 2006 and 2005 would have been as follows:

	Nine Months Ended		Three Months Ended	
	2006	2005	2006	2005
	----	----	----	----
Net income as reported (in thousands)	\$307,642	\$248,416	\$106,065	\$ 96,784
Deduct: Total stock-based employee compensation expense determined under the fair value method for all awards net of related tax effects (in thousands)	6,812	4,694	2,362	1,660
	-----	-----	-----	-----
Pro forma net income (in thousands)	\$300,830	\$243,722	\$103,703	\$ 95,124
	=====	=====	=====	=====
Earning per share:				
Basic, as reported	\$1.24	\$0.98	\$0.43	\$0.38
	=====	=====	=====	=====
Basic, pro forma	\$1.21	\$0.96	\$0.42	\$0.38
	=====	=====	=====	=====
Diluted, as reported	\$1.23	\$0.97	\$0.43	\$0.38
	=====	=====	=====	=====
Diluted, pro forma	\$1.21	\$0.96	\$0.42	\$0.37
	=====	=====	=====	=====

In December 2004, the FASB issued SFAS No. 123(R), "Share-Based Payment", which is a revision to SFAS No. 123, "Accounting for Stock Based Compensation". SFAS 123(R) requires all share-based payments to employees, including stock options, to be expensed based on their fair values over the required award service period. Although it is difficult to predict the exact impact the adoption of SFAS 123(R) will have on the Company's consolidated earnings due to the number of variables involved, we believe the above pro forma disclosures provide an appropriate indicator of the level of expense that may be recognized upon adoption of the statement. The SEC has amended the compliance dates of SFAS

Edgar Filing: BIOMET INC - Form 10-Q

123(R) requiring adoption in the first fiscal year beginning after June 15, 2005. The Company intends to adopt SFAS 123(R) on June 1, 2006.

NOTE 2: COMPREHENSIVE INCOME.

Other comprehensive income includes foreign currency translation adjustments and unrealized appreciation of available-for-sale securities, net of taxes. Other comprehensive income for the three months ended February 28, 2006 and 2005 was \$7,701,000 and \$8,620,000, respectively. Other comprehensive income for the nine months ended February 28, 2006 and 2005 was \$(21,223,000 and \$27,151,000, respectively. Total comprehensive income combines reported net income and other comprehensive income. Total comprehensive income for the three months ended February 28, 2006 and 2005 was \$113,766,000 and \$105,404,000, respectively. Total comprehensive income for the nine months ended February 28, 2006 and 2005 was \$286,419,000 and \$275,567,000, respectively.

NOTE 3: INVENTORIES.

Inventories at February 28, 2006 and May 31, 2005 are as follows:

	February 28, 2006	May 31, 2005
	-----	-----
	(in thousands)	
Raw materials	\$ 67,652	\$ 50,676
Work-in-process	55,862	56,610
Finished goods	222,636	200,041
Consigned inventory	177,173	162,464
	-----	-----
	\$523,323	\$469,791
	=====	=====

NOTE 4: COMMON SHARES.

During the nine months ended February 28, 2006, the Company issued 649,814 Common Shares upon the exercise of outstanding stock options for proceeds aggregating \$12,598,000. Purchases of Common Shares pursuant to the Common Share Repurchase Programs aggregated 4,456,400 shares for \$159,122,000 during the nine months ended February 28, 2006.

NOTE 5: EARNINGS PER SHARE.

Earnings per common share amounts ("basic EPS") are computed by dividing net income by the weighted average number of common shares outstanding and excludes any potential dilution. Earnings per common share amounts assuming dilution ("diluted EPS") are computed by reflecting potential dilution from the exercise of stock options.

NOTE 6: INCOME TAXES.

The difference between the reported provision for income taxes and a provision computed by applying the federal statutory rate to pre-tax accounting income is primarily attributable to state income taxes, tax benefits relating to operations in Puerto Rico, tax-exempt income and tax credits.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

On Monday, March 27, 2006, The Board of Directors of Biomet, Inc. announced

Edgar Filing: BIOMET INC - Form 10-Q

that Dane A. Miller, Ph.D., the Company's President and Chief Executive Officer and a co-founder, has informed the Board of his decision to retire and has resigned. He will remain a Director and serve as a consultant. The Board has appointed Senior Vice President Daniel P. Hann, the Company's General Counsel and a member of the Board, to be President and Chief Executive Officer on an interim basis.

FINANCIAL CONDITION AS OF FEBRUARY 28, 2006

The Company's cash and investments decreased \$7,238,000 to \$169,836,000 at February 28, 2006. This decrease resulted from the \$62,473,000 dividend payment made during the first quarter and the \$159,122,000 used to purchase shares during the first nine months pursuant to the Company's share repurchase programs, offset by positive cash flow from operations. On December 21, 2005, the Company announced an expansion to its discretionary share repurchase program to add an additional \$100 million.

Cash flows provided by operating activities were \$277,938,000 for the first nine months of fiscal 2006 compared to \$284,716,000 in 2005. The primary sources of fiscal year 2006 cash flows from operating activities was net income adjusted for depreciation. The primary uses were increases in accounts receivable and inventory. The Company's major cash collection day is Monday, and as the Company's quarter end moves further away from a Monday, accounts receivable ending balances increase. Inventories increased from new product introductions, specifically the Oxford, Vanguard and OSS knee systems, the Magnum hip system, the ReCap resurfacing system and the Polaris spine system. In addition, the Company increased inventory for the launch of its new bone cements, while maintaining adequate supplies of its previous products. Accounts and notes receivable and inventory balances were decreased during the nine month period by \$10.6 million and \$12.8 million, respectively, due to currency exchange rates.

Cash flows used in investing activities were \$68,424,000 for the first nine months of fiscal 2006 compared to \$337,672,000 in 2005. The primary use of cash flows from investing activities in fiscal 2006 has been for capital expenditures. The Company continues to upgrade its instruments used in various international markets and to support the new implant systems being launched. In addition, 3i is currently expanding its manufacturing facilities in Florida. Last years investing activities included the acquisition of Interpore.

Cash flows used in financing activities were \$213,677,000 for the first nine months of fiscal 2006 compared to a use of \$3,078,000 in 2005. The primary uses of cash flows in financing activities were the cash dividend paid and the share repurchase programs. In July 2005, the Company's Board of Directors declared a cash dividend of twenty five cents (\$0.25) per share payable to shareholders of record at the close of business on July 16, 2005. Over the last thirteen quarters, the Company has used \$1 billion to purchase its common stock.

Currently available funds, together with anticipated cash flows generated from future operations are believed to be adequate to cover the Company's anticipated cash requirements, including capital expenditures, research and development costs and share repurchases.

RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED FEBRUARY 28, 2006 AS COMPARED TO THE NINE MONTHS ENDED FEBRUARY 28, 2005

Net sales increased 8% to \$1,485,847,000 for the nine months ended February 28, 2006, from \$1,376,857,000 for the same period last year. Excluding the impact from foreign currency, net sales grew 9%. The Company's sales were

Edgar Filing: BIOMET INC - Form 10-Q

impacted by the hurricane activity in the gulf coast and Florida, resulting in an estimated revenue loss of approximately \$4.5 million. The Company's U.S.-based revenue increased 6% to \$975,605,000 during the first nine months of fiscal 2006, while foreign sales increased 11% (13% currency adjusted) to \$510,242,000. The Company's worldwide sales of reconstructive products during the first nine months of fiscal 2006 were \$1,006,764,000, representing an 11% increase compared to the first nine months of last year. Sales of fixation products were \$187,192,000 for the first nine months of fiscal 2006, representing a 1% increase as compared to the same period in 2005. Sales of spinal products were \$164,267,000 for the first nine months of fiscal 2006, representing a 3% increase as compared to the same period in 2005. Fixation and spinal product sales have been negatively impacted by the combination of the Interpore and EBI sales forces, and at the same time the integration of Biomet's internal fixation sales force into EBI's fixation sales force. During the fourth quarter of last year and the first quarter of this year, EBI has introduced several new products in both the internal fixation and spinal implant markets that we believe will have a positive impact on sales in the future. In addition, during the first quarter, the Company announced the appointment of Bart Doedens, M.D., as the new president of EBI's operations following the resignation of James R. Pastena. EBI's fixation, spinal stimulation and softgoods and bracing products have continued to underperform management's expectations and it is hoped that Dr. Doedens will provide the leadership necessary to improve EBI's performance in these markets. The Company's sales of other products totaled \$127,624,000, representing a 4% increase over the first nine months of fiscal year 2005.

Cost of sales decreased as a percentage of net sales to 28.0% for the first nine months of fiscal 2006 from 28.7% for the same period last year. The components of this change are a decrease of 1.6% relating to the impact of inventory step-up from acquisitions on last year's cost of goods sold, offset by an increase of 0.3% due to an unanticipated, retroactive price increase from the supplier of Biomet's antibiotic delivery system in Europe and 0.6% from higher growth rates in foreign sales, where gross margins are lower, versus domestic sales. Selling, general and administrative expenses, as a percentage of net sales, were flat at 36.7%. Research and development expenditures increased 7.9% during the first nine months to \$63,182,000 reflecting the Company's continued emphasis on new product introductions. In-process research and development expense relates to the acquired in-process research and development related to the Interpore acquisition completed last year, which was written off at the acquisition date. Operating income increased 18% from \$391,150,000 for the first nine months of fiscal 2005, to \$460,726,000 for the first nine months of fiscal 2006. After adjusting operating income for acquisition related expenses in fiscal 2005, operating income increased 5%. Other income increased from \$2,157,000 last year to \$2,575,000 this year. Other income has been positively impacted by higher daily balances of investments during the first quarter and an increase in interest rates. The effective income tax rate decreased to 33.6% for the first nine months of fiscal year 2006 from 36.8% last year primarily as a result of the write-off of in-process research and development last year not being tax affected.

These factors resulted in a 24% increase in net income from \$248,416,000 to \$307,642,000, a 27% increase in basic earnings per share from \$0.98 to \$1.24 and a 27% increase in diluted earnings per share from \$0.97 to \$1.23 for the periods presented. Before acquisition related expenses last year, net income increased by 7%, basic and diluted earnings per share increased 9% for the periods presented.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED FEBRUARY 28, 2006
AS COMPARED TO THE THREE MONTHS ENDED FEBRUARY 28, 2005

Edgar Filing: BIOMET INC - Form 10-Q

Net sales increased 5% to \$506,254,000 for the third quarter ended February 28, 2006, from \$482,023,000 for the same period last year. Excluding the impact from foreign currency, net sales grew 8%. The Company's U.S.-based revenue increased 6% to \$332,678,000 during the third quarter of fiscal 2006, while foreign sales increased 3% to \$173,576,000. Excluding the foreign currency adjustment, foreign revenue increased 11%. The Company's worldwide sales of reconstructive products during the third quarter of fiscal 2006 were \$346,610,000, representing a 6% increase (10% excluding foreign currency) compared to the third quarter of last year. Sales of fixation products were \$62,338,000 for the third quarter fiscal 2006, representing a slight increase (2% excluding foreign currency) as compared to the same period in 2005. Sales of spinal products were \$53,914,000 for the third quarter of fiscal 2006, representing a 2% increase (3% excluding foreign currency) as compared to the same period in 2005. Fixation and spinal product sales have been negatively impacted by the combination of the Interpore and EBI sales forces, and at the same time the integration of Biomet's internal fixation sales force into EBI's fixation sales force. The Company expects this negative impact to continue during the next quarter. The Company's sales of other products totaled \$43,392,000, representing a 6% increase (8% excluding foreign currency) over the third quarter of fiscal year 2005.

Cost of sales decreased as a percentage of net sales to 28.3% for the third quarter of fiscal 2006 from 28.6% for the same period last year. The components of this change are a decrease of 1.5% relating to the impact of inventory step-up from acquisitions on last year's cost of goods sold, offset by an increase of 0.2% due to an unanticipated price increase from the supplier of Biomet's antibiotic delivery system in Europe and 1% from lower gross margins, mainly from international sales. Selling, general and administrative expenses, as a percentage of net sales, decreased to 36.6% compared to 37.2% for the third quarter last year. This decrease is mainly attributable to lower selling expenses in the bone healing product line offset by the national branding campaign commenced during the first quarter. Research and development expenditures increased 3% during the third quarter to \$21,063,000 reflecting the Company's continued emphasis on new product introductions. Operating income increased 9% from \$144,270,000 for the third quarter of fiscal 2005, to \$156,993,000 for the third quarter of fiscal 2006. After adjusting operating income for acquisition related expenses in fiscal 2005, operating income increased 4%. Other income decreased from \$2,641,000 last year to \$2,262,000 this year. Other income has been negatively impacted by a reduction in cash available for investments due to the large amount of shares repurchased during the third quarter. The effective income tax rate decreased to 33.4% for the quarter from 34.1% last year.

These factors resulted in a 10% increase in net income to \$106,065,000 for the third quarter of fiscal 2006 as compared to \$96,784,000 for the same period in fiscal 2005, while basic and diluted earnings per share increased 13%, from \$0.38 to \$0.43 for the periods presented. Before acquisition related expenses last year, net income increased by 4%, while basic and diluted earnings per share increased 8% for the periods presented.

Item 3. Quantitative and Qualitative Disclosures about Market Risks.

There have been no material changes from the information provided in the Company's Annual Report on Form 10-K for the year ended May 31, 2005.

Item 4. Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of its management, including the

Edgar Filing: BIOMET INC - Form 10-Q

Company's Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934). Based on this evaluation, the Company's Chief Executive Officer and Chief Financial Officer have concluded that the Company's disclosure controls and procedures are effective in timely notification to them of information the Company is required to disclose in its periodic SEC filings and in ensuring that this information is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and regulations.

(b) Changes in Internal Control. During the third quarter of fiscal 2006 covered by this report, there have been no changes in internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

(c) Stock Repurchases

As of February 28, 2006, the Company had two publicly-announced share repurchase programs outstanding. The first, announced June 30, 2005, approved the purchase of 2,500,000 shares to be automatically purchased in equal installments over a twelve-month period expiring June 29, 2006. The second, announced December 21, 2006, approved the purchase of shares up to \$100 million in open market or privately negotiated transactions expiring December 20, 2006. The march 20, 2005 plan authorization has been exhausted. Information on shares repurchased in the most recently completed quarter is as follows:

Period	Total Number of shares Purchased	Average Price Paid Per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans	Maximum Number of Shares (or Approximate Dollar Value) that May Yet be Purchased Under the Plans
December 1-31	210,000	\$37.06	210,000	1,240,000 shares and \$118,017,406
January 1-31	1,281,800	36.25	1,281,800	1,040,000 shares and \$78,849,931
February 1-28	190,000	36.53	190,000	830,000 shares and \$78,849,931
Total	1,681,800	36.39	1,681,800	830,000 shares and \$78,849,931

Item 6. Exhibits.

See Index to Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIOMET, INC.

Edgar Filing: BIOMET INC - Form 10-Q

DATE: 4/10/2006

BY: /s/ Gregory D. Hartman

Gregory D. Hartman
Senior Vice President - Finance
(Principal Financial Officer)

(Signing on behalf of the registrant
and as principal financial officer)

BIOMET, INC.

FORM 10-Q

INDEX TO EXHIBITS

Exhibits.	Descriptions.
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Written Statement of Chief Executive Officer and Chief Financial Officer Pursuant to Sections 906 of the Sarbanes-Oxley Act of 2002.